AstraZeneca (NASDAQ:AZN – Get Free Report) released its quarterly earnings results on Thursday. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05), Zacks reports. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%.
AstraZeneca Stock Up 2.0 %
AstraZeneca stock opened at $72.36 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $67.38 and its 200 day moving average price is $73.69. AstraZeneca has a 52 week low of $60.47 and a 52 week high of $87.68. The firm has a market cap of $224.39 billion, a price-to-earnings ratio of 34.62, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $89.75.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- 3 Dividend Kings To Consider
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- How Can Investors Benefit From After-Hours Trading
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
